BOSTON, July 16, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...
Cue Biopharma, Inc. has announced that it has received positive Pre-Investigational New Drug (Pre-IND) feedback from the FDA regarding its planned first-in-human trial for CUE-401, a novel bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results